Diane K Wysowski

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Use of parenteral iron products and serious anaphylactic-type reactions
    Diane K Wysowski
    Office of Surveillance and Epidemiology, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Am J Hematol 85:650-4. 2010
  2. ncbi Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, White Oak, Bldg 22, Room 3424, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Arch Intern Med 167:1414-9. 2007
  3. ncbi Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Anesthesiology 105:1047-51. 2006
  4. ncbi Surveillance of prescription drug-related mortality using death certificate data
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Drug Saf 30:533-40. 2007
  5. ncbi Trends in outpatient prescription drug use and related costs in the US: 1998-2003
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, Rockville, Maryland, USA
    Pharmacoeconomics 24:233-6. 2006
  6. ncbi Use of menopausal hormones in the United States, 1992 through June, 2003
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Pharmacoepidemiol Drug Saf 14:171-6. 2005
  7. ncbi Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Arch Intern Med 165:1363-9. 2005
  8. ncbi Deaths attributed to X-ray contrast media on U.S. death certificates
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, HFD-433, Silver Spring, MD 20993, USA
    AJR Am J Roentgenol 186:613-5. 2006
  9. ncbi Use of medications for erectile dysfunction in the United States, 1996 through 2001
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, Maryland, USA
    J Urol 169:1040-2. 2003
  10. ncbi Comparison of reported and expected deaths in sildenafil (Viagra) users
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Am J Cardiol 89:1331-4. 2002

Collaborators

  • Parivash Nourjah
  • James L Mills
  • Paul Brown
  • Lawrence B Schonberger
  • Judith E Fradkin
  • Christopher Cox
  • Stephen J Durako
  • Fanhui Kong

Detail Information

Publications15

  1. ncbi Use of parenteral iron products and serious anaphylactic-type reactions
    Diane K Wysowski
    Office of Surveillance and Epidemiology, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Am J Hematol 85:650-4. 2010
    ..To help differentiate risk among the parenteral iron products, the brand name of the product always should be provided on medical records, death certificates, and adverse drug reaction reports...
  2. ncbi Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, White Oak, Bldg 22, Room 3424, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Arch Intern Med 167:1414-9. 2007
    ..Warfarin sodium is widely used and causes bleeding; a review might suggest the need for regulatory action by the US Food and Drug Administration (FDA)...
  3. ncbi Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Anesthesiology 105:1047-51. 2006
  4. ncbi Surveillance of prescription drug-related mortality using death certificate data
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Drug Saf 30:533-40. 2007
    ..The prescription drugs or drug classes that are most frequently associated with death in the US might be identifiable from death certificate data...
  5. ncbi Trends in outpatient prescription drug use and related costs in the US: 1998-2003
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, Rockville, Maryland, USA
    Pharmacoeconomics 24:233-6. 2006
    ..CONCLUSIONS: These data indicate a large increase in the US over a short time period in dispensed outpatient prescriptions and their associated retail costs...
  6. ncbi Use of menopausal hormones in the United States, 1992 through June, 2003
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Pharmacoepidemiol Drug Saf 14:171-6. 2005
    ....
  7. ncbi Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Arch Intern Med 165:1363-9. 2005
    ..We encourage physicians, pharmacists, other health care professionals, and patients to continue to report serious suspected and known adverse drug reactions to manufacturers and the Food and Drug Administration...
  8. ncbi Deaths attributed to X-ray contrast media on U.S. death certificates
    Diane K Wysowski
    Division of Drug Risk Evaluation, Food and Drug Administration, HFD-433, Silver Spring, MD 20993, USA
    AJR Am J Roentgenol 186:613-5. 2006
    ..Names of administered contrast agents should be recorded in patients' medical records and communicated to primary care physicians and certifiers of death in the event of serious sequelae after an identified recent radiologic procedure...
  9. ncbi Use of medications for erectile dysfunction in the United States, 1996 through 2001
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, Maryland, USA
    J Urol 169:1040-2. 2003
    ..The data indicate the wide adoption and use of sildenafil for erectile dysfunction...
  10. ncbi Comparison of reported and expected deaths in sildenafil (Viagra) users
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Am J Cardiol 89:1331-4. 2002
  11. ncbi Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, Maryland 20857, USA
    Diabetes Care 26:1852-5. 2003
    ..To describe the use of oral antidiabetic drugs for management of type 2 diabetes in the U.S. from 1990 through 2001...
  12. ncbi Sex and age differences in serum potassium in the United States
    Diane K Wysowski
    Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA
    Clin Chem 49:190-2. 2003
  13. ncbi Use of inhalant medications with and without chlorofluorocarbon propellants in the United States, 1996-2000
    Diane K Wysowski
    Division of Drug Risk Evaluation, Office of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
    J Allergy Clin Immunol 110:51-3. 2002
  14. ncbi Analyzing prescription drugs as causes of death on death certificates
    Diane K Wysowski
    Public Health Rep 119:520. 2004
  15. ncbi Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients
    James L Mills
    National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, 6100 Building Room 7B03, Bethesda, MD 20892, USA
    J Pediatr 144:430-6. 2004
    ..We investigated whether they were at increased risk of death from other conditions, particularly preventable conditions...